# Daniel Heller

> Daniel Heller is a Series A investor at Affinity Asset Advisors backing Therapeutics. See 3 investments, round sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Affinity Asset Advisors](https://shizune.co/investors/profile/affinity-asset-advisors)
- Location: Zürich, Switzerland
- Total investments: 3
- Last investment: Jun 2023
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/danielheller-farner

Daniel Heller is a Series A investor at Affinity Asset Advisors in Zürich focused on Therapeutics and Biotechnology. Daniel Heller currently works as the General Partner and Chief Investment Officer for Affinity Asset Advisors.

## Contacts

5 contacts available for Daniel Heller: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/daniel-heller-d065?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Software | 1 | 33% |
| Health Care | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Seed | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Moodtalk | The goal of Moodtalk is to empower employees to identify team difficulties early on, address them, and instantly implement appropriate remedies. Moodtalk's software adds structure to human dialogue, distributes solutions and inspiration, and makes behavioral changes measurable in culture transformation and strategy execution processes. | $1.1M | Seed | Jun 15, 2023 | https://www.moodtalk.ch |
| Ceptur Therapeutics | Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS). | $75M | Series A | Jan 19, 2022 | https://www.Cepturtx.com |
| Kurome Therapeutics | Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy. The company is developing therapies that target cancer cells that have co-opted immune signaling pathways to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. | $15M | Series A | Jun 10, 2021 | https://kurometherapeutics.com |

3 of 3 investments shown.

## Co-investors
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 1 deal together
- [CincyTech](https://shizune.co/investors/profile/cincytech) — VC Fund, 1 deal together
- [innofund.vc](https://shizune.co/investors/profile/innofund-vc) — VC Fund, 1 deal together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 1 deal together
- [LifeSci Venture Partners](https://shizune.co/investors/profile/lifesci-venture-partners) — VC Fund, 1 deal together

## About Affinity Asset Advisors

VC Fund · New York, United States

Affinity Asset Advisors is a healthcare-focused hedge fund with public and private investments. The company is a hedge fund manager based in New York that was founded in 2018.

3 contacts available at Affinity Asset Advisors.

| Name | Title | Profile |
| --- | --- | --- |
| Daniel Heller | Partner and Chief Investment Officer | https://shizune.co/investors/profile/daniel-heller-d065 |
| Michael Cho | Managing Partner and Portfolio Manager | https://shizune.co/investors/profile/michael-cho-a849 |
| Patrick Nosker | Partner and Director of Research | https://shizune.co/investors/profile/patrick-nosker |

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors in Switzerland](https://shizune.co/investors/health-care-angel-investors-switzerland)
- [Enterprise Angel Investors in Switzerland](https://shizune.co/investors/enterprise-angel-investors-switzerland)

## FAQ

### What does Daniel Heller invest in?

Daniel Heller invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Daniel Heller?

Public channels for Daniel Heller include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Daniel Heller last invest?

The most recent investment recorded for Daniel Heller closed in Jun 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co